Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression

Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression

BackgroundT (8; 21) acute myeloid leukemia (AML) is a special type of acute leukemia, and exhibits a heterogeneous prognosis, with a long-term relapse rate of about 40%. Once t(8; 21) AML patients experience relapse, they have an extremely poor prognosis, with a 5-year overall survival rate of less...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaomin Zhang, Lixin Wang, Jingqiao Qiao, Shuhong Wang, Lijun Wang, Lian Liu, Jiading Qin, Ziren Chen, Wenfa Huang, Yuanyuan Zheng, Huixin Peng, Junhui Mei, Hongxin Wang, Chuan Yu, Yisheng Li, Li Yu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
t(8; 21) acute myeloid leukemia
aberrant CD19 expression
CD19 CAR-T cell therapy
hematological remission
molecular remission
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617589/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617589/full

Similar Items